AMADIX

Founded in 2010, Advanced Marker Discovery, S.L. (AMADIX) is a leading Spanish molecular diagnostics company focused on developing innovative diagnostic tests for early cancer detection, which impact patient survival and quality of life. The Company’s non-invasive assays tested in blood are oriented to avoid the complications and side effects of invasive procedures and to improve on the accuracy and compliance of currently marketed non-invasive tests. The company’s lead micro-RNA (miRNA) based gene signature test, ColoFast, for colorectal cancer (CRC) detection is currently undergoing a prospective clinical validation study and is planned to obtain CE-Mark and to be launched in 2018. The Company’s test pipeline includes blood-based tests for early detection of lung and pancreatic cancer.